SCHEMBL483635

SCHEMBL483635

COc1ccc(C(=O)NCC2CCC(C(=O)O)CC2)cc1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CXCR3 P49682 2/20 0.58
HPGD P15428 2/20 0.56
SMN1; SMN2 Q16637 2/20 0.56
L3MBTL1 Q9Y468 1/20 0.56
MMP13 P45452 1/20 0.54
HDAC3 O15379 1/20 0.53
HDAC4 P56524 1/20 0.53
HDAC1 Q13547 1/20 0.53
HDAC7 Q8WUI4 1/20 0.53
HDAC2 Q92769 1/20 0.53
HDAC10 Q969S8 1/20 0.53
HDAC11 Q96DB2 1/20 0.53
HDAC8 Q9BY41 1/20 0.53
HDAC6 Q9UBN7 1/20 0.53
HDAC9 Q9UKV0 1/20 0.53
HDAC5 Q9UQL6 1/20 0.53
ALDH1A1 P00352 3/20 0.53
VCP P55072 1/20 0.53
GAA P10253 1/20 0.52
KDM4E B2RXH2 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL483633 1.00 CXCR3 (0.58) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13
SCHEMBL11757383 0.92 SMN1; SMN2 (0.64) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13
SCHEMBL11760297 0.92 SMN1; SMN2 (0.64) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13
SCHEMBL4396197 0.87 SMN1; SMN2 (0.60) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13
SCHEMBL8598520 0.83 HDAC3 (0.64) HPGDSMN1; SMN2HDAC3HDAC4HDAC1
SCHEMBL7487285 0.83 HDAC3 (0.64) HPGDSMN1; SMN2HDAC3HDAC4HDAC1
Hydrochloric Acid SCHEMBL27583097 0.81 HTR4 (0.60) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13
SCHEMBL30989205 0.81 VCP (0.61) HPGDSMN1; SMN2ALDH1A1VCPGAA
SCHEMBL10185047 0.81 NPC1 (0.55) HPGDSMN1; SMN2L3MBTL1ALDH1A1GAA
SCHEMBL4005112 0.81 MAPK14 (0.55) CXCR3HPGDSMN1; SMN2L3MBTL1MMP13

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2024203441-A1 POWDERY SOLID COSMETIC 株式会社 資生堂 2024-10-03 WO disclosed
US-12029303-B2 Method for preparation of a cosmetic kit SHISEIDO COMPANY, LTD. (JP) 2024-07-09 US disclosed
US-20240207159-A1 SKIN PENETRATION IMPROVER KANEKA CORPORATION (JP) 2024-06-27 US disclosed
WO-2024080290-A1 MELANIN PIGMENT SYNTHESIS INHIBITOR 一丸ファルコス株式会社 2024-04-18 WO disclosed
EP-3597174-B1 TWO-COMPONENT COSMETIC SHISEIDO CO LTD (JP) 2024-04-17 EP disclosed
US-20230354983-A1 METHOD FOR PREPARATION OF A COSMETIC KIT SHISEIDO COMPANY, LTD. (JP) 2023-11-09 US disclosed
WO-2023032743-A1 SKIN PENETRATION IMPROVER 株式会社カネカ 2023-03-09 WO disclosed
US-20220395445-A1 WATER-IN-OIL EMULSION SUNSCREEN COSMETIC SHISEIDO COMPANY, LTD. (JP) 2022-12-15 US disclosed
US-11147750-B2 Two-component cosmetic SHISEIDO COMPANY, LTD. (JP) 2021-10-19 US disclosed
US-20200281340-A1 CUSTOMIZED COSMETIC KIT SHISEIDO COMPANY, LTD. (JP) 2020-09-10 US disclosed
EP-2087903-A1 EXTRACT POWDER OF INDIGO-CONTAINING PLANT, METHOD FOR PRODUCTION THEREOF, AND USE THEREOF Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) 2009-08-12 EP disclosed
US-20090047312-A1 Microgel and external compositions containing the same SHISEIDO CO., LTD. (JP) 2009-02-19 US disclosed
US-20080124367-A1 Oil Based Composition For External Use On Skin For Enhancing Percutaneous Absorption SHISEIDO COMPANY, LTD. (JP) 2008-05-29 US disclosed
EP-1894558-A1 AGENT FOR EXTERNAL APPLICATION TO THE SKIN Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo (JP) 2008-03-05 EP disclosed
EP-1839647-A1 OILY SKIN COMPOSITION FOR EXTERNAL USE FOR ACCELERATING PERCUTANEOUS ABSORPTION SHISEIDO COMPANY, LTD. (JP) 2007-10-03 EP disclosed
EP-1402875-A1 POWDERY COMPOSITION SHISEIDO COMPANY, LTD. (JP) 2004-03-31 EP disclosed
US-20040028710-A1 Process for producing dry water SHISEIDO COMPANY, LTD. (JP) 2004-02-12 US disclosed
EP-1386599-A1 PROCESS FOR PRODUCING DRY WATER SHISEIDO COMPANY, LTD. (JP) 2004-02-04 EP disclosed
US-20030202993-A1 Powdery composition SHISEIDO COMPANY, LTD. (JP) 2003-10-30 US disclosed
EP-1158021-A1 MICROGELS AND EXTERNAL PREPARATIONS CONTAINING THE SAME SHISEIDO COMPANY LIMITED (JP) 2001-11-28 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240207159-A1 SKIN PENETRATION IMPROVER CUTA, NAPEPLD, PLTP CXCR3 2178/4885HPGD 2853/4885SMN1; SMN2 3648/4885
US-20030202993-A1 Powdery composition CUTA, FLNA, FERMT2 CXCR3 3593/4885HPGD 4241/4885SMN1; SMN2 1453/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.